Pyridam Farma (PYFA) Expands Access to Lipid Disorder Therapies, Supporting Cardiovascular Risk Factor Management

3 min read

KEY POINTS:

JAKARTA, October 4, 2026 – PT Pyridam Farma Tbk (IDX: PYFA) has officially received Marketing Authorization (NIE) from the Indonesian Food and Drug Authority (BPOM RI) for its product containing Fenofibrate 145 mg. The approval was presented directly by the Head of BPOM RI, Prof. dr. Taruna Ikrar, M.Biomed., Ph.D., to the Company’s Director, Bedjo Stefanus, in Bandung, West Java. This milestone highlights the ongoing collaboration between the pharmaceutical industry and the government to expand access to lipid disorder therapies as part of broader efforts to manage cardiovascular risk factors in Indonesia.

Fenofibrate is a therapeutic agent in the fibrate class that helps lower triglyceride levels and improve lipid profiles in the blood—including reducing LDL cholesterol—while stimulating an increase in HDL cholesterol levels. Optimal lipid management plays a crucial role in controlling risk factors associated with plaque formation, which can lead to the narrowing or blockage of arteries.

Responding to this regulatory milestone, the Company emphasized that this achievement aligns with its long-term vision. The product is expected to become a reliable therapeutic option for healthcare professionals across Indonesia. PYFA Director Bedjo Stefanus noted that this achievement opens up significant opportunities to expand the company’s product portfolio.

“For us, securing Marketing Authorization is not just a regulatory milestone; it opens doors for PYFA to continuously broaden our portfolio and deliver more healthcare solutions that meet the needs of the Indonesian public,” said Bedjo.

For PYFA, every regulatory milestone serves as a stepping stone to strengthen capabilities and expand its contribution to the national healthcare landscape. Expanding access to Fenofibrate-based treatment represents a strategic intervention by the company to provide essential therapeutic options for patients with lipid disorders.

The urgency for accessible treatment is becoming increasingly critical amid the rising burden of non-communicable diseases in Indonesia, particularly cardiovascular disease and stroke. Beyond impacting public health, these conditions impose a substantial financial strain on the national healthcare system. According to data from the Ministry of Health of the Republic of Indonesia in its Indonesia Health Profile publication, heart disease and stroke consistently rank as the top two causes of death, claiming up to 1.5 million lives annually. The latest BPJS Kesehatan report in September 2026 also revealed that heart disease accounts for the highest medical expenditure at IDR 17.35 trillion, followed by stroke at IDR 7.21 trillion. PYFA’s new product is expected to contribute to long-term efforts aimed at easing both the disease burden and national healthcare spending.

PYFA remains committed to delivering high-value innovations to mitigate the surge in non-communicable diseases. This commitment is reflected in the accelerated expansion of the company’s manufacturing facilities. Currently, the Line 3 sterile injection production facility has completed construction and is scheduled to enter commercial production in early 2027.

About PYFA

PT Pyridam Farma Tbk, also known as PYFA, is a public pharmaceutical company listed on the Indonesia Stock Exchange (Ticker: PYFA). PYFA operates several business units producing prescription medicines in various forms, including tablets, capsules, creams, and injections. PYFA also has several well-known subsidiaries, including PT Holi Pharma, PT Ethica Industri Farmasi, and Probiotec Multipack.